{{ (moduleVm.actions && moduleVm.changeStatus) ? moduleVm.status : '' }} Menopausal Hormone Therapy for Vasomotor Symptoms: 18 Years After the Women's Health Initiative - Vol. 41, No. 8

Activity Steps


Method of Participation in the Learning Process/Evaluation Method

Successful completion of this activity includes reading the entire article and successfully completing the post-quiz and an evaluation form.

Getting the Most out of the Activity

As you prepare to participate in this activity, please reflect on your practice and your patients and identify clinical challenges you hope to have addressed.

While participating in the training, identify ways you can use newly acquired knowledge, strategies, and skills to enhance patient outcomes and your own professional development.

Learning Objectives

After completing this continuing education activity you will be able to:

  1. Identify the pathophysiology and risk factors associated with menopausal vasomotor symptoms.
  2. Explain the risks and benefits of menopausal hormone therapy (MHT).
  3. Plan MHT treatment options for postmenopausal patients experiencing symptoms caused by estrogen deprivation.
Price: $49.00


  • ACCME 2.0 CME

Lippincott Continuing Medical Education Institute, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Lippincott Continuing Medical Education Institute, Inc. designates this enduring material for a maximum of 2.0 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Professions: Physician
Test Code: PGO0521B
Published: May 30, 2021
Expires: 5/29/2023
Required Passing Score: 7/10 (70%)
Authors: Kayla Ostiller, BS, Alexandra Lebental, MD, and Marisa Z. Rose, MD
Specialties: Gynecology, OB/GYN